Visterra, Inc.
275 2nd Avenue
Waltham
Massachusetts
02451
United States
Tel: 6174012031
Website: http://www.visterrainc.com/
Email: careers@visterrainc.com
About Visterra, Inc.
Visterra is a clinical stage biotechnology company committed to developing innovative antibody-based therapies for the treatment of patients with kidney diseases and other hard-to-treat diseases. Our proprietary technology platform enables the design and engineering of precision antibody-based product candidates that specifically bind to, and modulate, key disease targets. Applying this technology to disease targets that are not adequately addressed by traditional therapeutic approaches, we are developing a robust pipeline of novel therapies for patients with unmet needs.
43 articles about Visterra, Inc.
-
Visterra Presents Data Demonstrating Safety, Tolerability and Positive Clinical Activity Trends of VIS410 in Non-Hospitalized Patients with Influenza A
11/15/2018
Visterra, Inc., a clinical stage biotechnology company, announced today that its Phase 2a study of VIS410, a novel monoclonal antibody, demonstrated safety, tolerability and clinical activity trends in non-hospitalized patients with influenza A.
-
Visterra Initiates Phase 1 Clinical Study of VIS649
11/8/2018
Novel Monoclonal Antibody for the Treatment of IgA Nephropathy
-
Otsuka Pharmaceutical Completes Acquisition of Visterra
9/4/2018
Visterra will operate as a wholly owned subsidiary of Otsuka America, Inc., which is a U.S. holding company and a wholly owned subsidiary of Otsuka Pharmaceutical Co., Ltd. of Japan.
-
Otsuka Pharmaceutical to Acquire Visterra
7/11/2018
Otsuka will acquire Visterra for approximately USD 430 million in an all-cash transaction.
-
Otsuka Pharmaceutical, based in Tokyo, Japan, is acquiring Waltham, Massachusetts-based Visterra for $430 million in cash. The deal is expected to close in the third quarter of this year.
-
Visterra to Present New Preclinical Data on VIS410 for Influenza A at the International Meeting on Respiratory Pathogens
3/7/2018
Visterra, Inc. today announced that it will present new preclinical data on VIS410, a novel monoclonal antibody in development for treatment of hospitalized patients with influenza A, at the 2nd International Meeting on Respiratory Pathogens, at the Grand Copthorne Waterfront Hotel in Singapore, on March 7 - 9, 2018.
-
Visterra Announces Publication in the Journal PLOS Neglected Tropical Diseases Demonstrating that Novel Antibody, VIS513, Broadly Neutralizes Antibody-Enhanced Dengue Infection in Preclinical Studies
2/12/2018
Visterra announced that new preclinical results with VIS513, its novel monoclonal antibody in development for the treatment of dengue, were published online in the journal PLOS Neglected Tropical Diseases (Y. Budigi et al., PLoS Negl Trop Dis 12(2): e0006209. https://doi.org/10.1371/journal.pntd.0006209).
-
Visterra has outgrown its headquarters and is moving to a site double the size in suburban Waltham, MA.
-
The 2017 Biotech IPO Winners and Losers
12/21/2017
Although it was an average year for mergers and acquisitions in the biopharma industry, it was a stronger year for IPOs. -
FDA Grants Fast Track Designation to Visterra's VIS410 for Treatment of Hospitalized Patients with Influenza A
11/1/2017
Visterra is a clinical-stage biotechnology company that uses its novel Hierotope platform to identify unique disease targets and to design and engineer precision antibody-based biological medicines against such targets that are not adequately addressed with conventional approaches.
-
George Scangos' Bold Vision
10/25/2017
The former Biogen CEO is making waves at his new venture, Vir Biotechnology. -
Two weeks after securing more than $46M in financing, Visterra struck a deal worth up to $1B with startup Vir Biotech.
-
Vir Biotechnology Builds Pipeline, Capabilities, And Lays Out Strategy To Address Serious Infectious Diseases
10/18/2017
Vir Biotechnology, Inc. today announced agreements with Humabs BioMed SA, Alnylam Pharmaceuticals, Inc., and Visterra, Inc., as well as four leading academic research institutions.
-
Visterra Awarded CARB-X Contract To Advance Development Of VIS705
3/31/2017
-
Cambridge Biotech Visterra Scuttles Plans for $50 Million IPO
2/13/2017
-
Visterra, Inc. Release: Pharma Doses First Patient In Phase 2a Trial For VIS410, Its Monoclonal Antibody In Development For The Treatment Of Hospitalized Patients With Influenza A
1/11/2017
-
Visterra, Inc. Gears Up For IPO
12/27/2016
-
Visterra, Inc. To Present New Clinical Results Of VIS410 At The Options IX For The Control Of Influenza Conference
8/25/2016
-
Visterra, Inc. To Present New Clinical Results Of VIS410 At The Options IX For The Control Of Influenza Conference
8/24/2016
-
Visterra, Inc. Appoints Two Industry Leaders To Its Board Of Directors
4/21/2016